Indianapolis, INNCT07121244Now EnrollingIRB Ready

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer Clinical Trial in Indianapolis, IN

Access cutting-edge locoregionally recurrent hormone-receptor positive breast cancer treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.

Sponsored by Radionetics Oncology

Quick Self-Assessment

See if you qualify for this Indianapolis location

Preparing your pre-screening questions…

Expert Care in Indianapolis

Access locoregionally recurrent hormone-receptor positive breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related locoregionally recurrent hormone-receptor positive breast cancer treatment provided free

Apply for This Indianapolis Location

Check if you qualify for this locoregionally recurrent hormone-receptor positive breast cancer clinical trial in Indianapolis, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Indianapolis

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Indianapolis site if eligible
  4. 4Begin participation

About This Locoregionally Recurrent Hormone-receptor Positive Breast Cancer Study in Indianapolis

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.

Sponsor: Radionetics Oncology

Who Can Participate

Inclusion Criteria

Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer
At least one target or non-target lesion per RECIST v1.1 criteria.
Male or non-pregnant, non-lactating female subjects age ≥18 years. Part B
Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer
Refractory to endocrine therapy. Note: there is no limit on prior number of lines of endocrine therapy or prior treatments with CDK4/6, AKT, PI3K and/or mTOR inhibitors.
Received or declined at least one line of chemotherapy or antibody drug conjugate in the locoregionally recurrent or metastatic setting
Progressive disease or intolerance to last treatment.
At least one target lesion per RECIST v1.1 criteria.
Male or non-pregnant, non-lactating female subjects age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Life expectancy of at least six months.
Adequate bone marrow reserve, hepatic function and renal function.

Exclusion Criteria

Study participant has not recovered from clinically significant adverse event(s) resulting from most recent anticancer therapy/intervention.
Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period.
Radiotherapy for breast cancer ≤ 28 days prior
Received a radionuclide within a period of less than 10 physical half-lives of the administered radionuclide prior to dosing with 68Ga-R11228.
Any condition that precludes the proper performance of imaging procedures required in this study. Part B
Study participant has not recovered from clinically significant adverse event(s) resulting from most recent anticancer therapy/intervention
Treatment with anticancer therapy or with an investigational drug or device within 21 days or 5 half-lives of the agent (whichever is shorter)
Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period.
Radiotherapy for breast cancer ≤ 28 days
Prior systemic radionuclide therapeutic treatment.
Received a radionuclide within a period of less than 10 physical half-lives of the administered radionuclide prior to dosing with 68Ga-R11228.
Any unresolved NCI-CTCAE Version 5.0 Grade 2 or higher toxicity (except alopecia and Grade 2 platinum-therapy related neuropathy) from previous breast cancer treatment and/or from medical/surgical procedures or interventions.
Any condition that precludes the proper performance of imaging procedures required in this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Indianapolis?

Yes, this clinical trial (NCT07121244) has an active research site in Indianapolis, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer Treatment Options in Indianapolis, IN

If you're searching for locoregionally recurrent hormone-receptor positive breast cancer treatment options in Indianapolis, IN, this clinical trial (NCT07121244) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced locoregionally recurrent hormone-receptor positive breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all locoregionally recurrent hormone-receptor positive breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Indianapolis, IN

See all breast cancer clinical trials recruiting in Indianapolis — not just this study.

Browse Breast Cancer Trials in Indianapolis →

Browse More Trials by Condition

Breast Cancer TrialsLeukemia TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Indianapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Indianapolis, IN